LC

Lilly(Eli) & Company

LLY
NYSEHealth Care
$1,136.37
USD
-8.31(-0.73%)
At close: Jun 10, 20:00 UTC

Open

$1,137.05

Prev. Close

$1,137.17

High

$1,139.36

Low

$1,135.85

Market Snapshot

Market Cap

$1.08T

P/E Ratio

42.7

EPS

11.76

Revenue

$45.04B

Why LLY moved

Eli Lilly is expanding its portfolio through acquisitions and successful drug approvals, enhancing its presence in obesity and dermatology markets while addressing sleep apnea awareness.

About

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 50,000 full-time employees. The firm manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.

Recently from Cashu